REFINE-MS
Innovative trial to optimse treatment duration in relapsing–remitting MS
REFINE-MS is a clinical trial designed to determine the optimal treatment frequency of ocrelizumab for people with relapsing-remitting MS. The trial will test whether less frequent dosing can maintain control of MS disease activity while reducing infections, side effects, hospital visits, and healthcare costs.
Using a multi-arm, multi-stage (MAMS) trial design, REFINE-MS will compare the current standard 6-monthly dosing schedule with less frequent treatment approaches. This design allows the trial to identify the most effective and safest dosing strategy more efficiently than traditional clinical trials.
REFINE-MS is recruiting people with relapsing-remitting MS across the UK who have been clinically stable on ocrelizumab treatment. The study aims to improve long-term treatment safety, reduce treatment burden for people with MS, and support more sustainable NHS care.
For more information, please visit the REFINE-MS trial page: